Illumina scientist’s startup aims to rapidly detect drug resistance in bacterial DNA

green bacteria
Arc Bio's cloud software promises to detect drug resistance and provide annotations to any gram-negative DNA sequence in less than five minutes. (Gerd Altmann)

One of the founding scientists of Illumina has come out with a new gene-sequencing software startup that aims to tackle antimicrobial resistance and rapid pathogen detection.

Arc Bio launched with its first cloud-based product, Galileo AMR, which promises to detect possible drug resistance and provide annotations for any gram-negative bacterial DNA sequence in under five minutes. Tracking certain genes can help researchers better understand how drug resistance spreads through different strains.

Based in Menlo Park, California, and Cambridge, Massachusetts, Arc Bio’s CEO, Todd Dickinson, is joined by scientific co-founders Carlos Bustamante and David Andrew Sinclair. Bustamante is a population geneticist and professor of biomedical data science, genetics and biology at Stanford University, while Sinclair is a professor of genetics at Harvard University.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"As the CDC reports, every year over 2 million people are infected by antibiotic resistant bacteria, causing more than 23,000 deaths in the U.S.,” Dickinson said in a statement. “Rapid identification of various strains of antimicrobial resistance, and better understanding their transmission and evolution, is vital to protecting public health."

RELATED: Fighting superbugs with ‘supercharged’ antibiotics

Dickinson served as director of product development for Illumina’s DNA sequencing operations and spent more than 12 years with the company. He also served as VP of global commercial operations at BioNano Genomics.

Galileo AMR—formerly known as MARA and acquired from Spokade—draws from a digital archive of validated gram-negative AMR genes, cassettes and other mobile elements.

RELATED: Insights into gene network could expose new targets for drug-resistant infections

"Our goal at Arc Bio is to revolutionize pathogen detection by developing a unique NGS lab workflow and software solution that allows for smarter and simple to use analysis," Bustamante said. "Our current emphasis is on assisting those in public health and life science research who study antimicrobial resistance transmission and evolution of gram-negative bacteria."

Arc Bio, which operates under Sinclair’s EdenRoc Sciences, aims to build a suite of next-generation sequencing products in bacterial and pathogen analysis.

Suggested Articles

The FDA allowed manufacturers to file 1.1 million device reports to a little-known internal database, a Kaiser Health News investigation found.

Novartis, Otsuka, Pfizer and Sanofi will use technology from Verily’s Project Baseline to carry out clinical studies in various disease areas.

Ocular Therapeutix’s drug-eluting tear duct plug for glaucoma fell just short of the primary endpoint of its first phase 3 trial.